ANTITUMOUR AGENT INTENSIFIER Russian patent published in 2015 - IPC C07D239/54 C07D405/12 A61K31/513 A61P35/00 A61P35/02 A61P43/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new intensifier of the antitumour effect, which is a uracil derivative of the general formula (I) or its pharmaceutically acceptable salt. In the general formula (I) X represents a C_1-5-alkylene group, and wherein one of methylene groups making an alkylene group is optionally substituted by an oxygen atom; R¹ represents a hydrogen atom or a C_1-6-alkyl group; R² represents a hydrogen atom or a halogen atom; and R³ represents a C_1-6-alkyl group, C_2-6-alkenyl group, C_3-6-cycloalkyl group, (C_3-6-cycloalkyl)-C_1-6-alkyl group, halogen-C_1-6-alkyl group or a 5-6-merous saturated heterocyclic group with an oxygen atom as a heteroatom, a uracil derivative presented by the following formula (I). The invention also refers to a method for potentiating the antitumour action or a method of treating tumours, involving administering an effective amount of a combination of the above uracil derivative or its pharmaceutically acceptable salt and an antimetabolite in an effective amount. The antimetabolite represents an agent specified in 5-fluoruracil (5-FU), potassium tegafur/gimeracil/oteracil (TS-1), tegafur/uracil (UFT), capecitabin, 5-fluor-2'-deoxyuridine (FdUrd) and Pemetrexed.

EFFECT: preparing the intensifier of the antitumour effect.

18 cl, 10 dwg, 10 tbl, 67 ex